Deep 6 AI Announces Substantial Expansion of its Innovative AI-Based Clinical Trial Acceleration Software and Research Ecosystem

October 23, 2022

Experienced software and technology leaders Chris Brubaker and Talha F. Basit have joined the executive team as Chief Marketing and Customer Officer and Chief Technology Officer, respectively. “I started Deep 6 AI in 2016 to use the power of AI to rethink patient recruitment and trial feasibility in clinical research,” said Wout Brusselaers, CEO of Deep 6 AI. Most recently, Talha served as Chief Technology Officer for divvyDOSE, an online pharmacy that delivers personalized, presorted medication packs to patients. Prior to divvyDOSE, Talha was the Chief Technology Officer for Dose Media LLC, where helped secure $25M in Series B Funding. “This is an ideal time to join Deep 6 AI, and I couldn’t be more excited,” said Chris.

The source of this news is from Deep6 AI